Cinoxacin therapy for urinary tract infections: therapeutic safety and efficacy.
We gave cinoxacin to 125 patients with initial and recurrent urinary tract infections to investigate the safety and efficacy of this new antimicrobial agent. Patients ranging in age from 18 to 92 were treated with 500 mg twice daily for nine days. Analysis showed a satisfactory symptomatic response rate of 96% and a bacteriologic cure rate of 92%, with mild side effects observed in 6% of the participants.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use; D002937:Cinoxacin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011724:Pyridazines / Q000627:therapeutic use*; D012008:Recurrence; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000382:microbiology
D000892:Anti-Infective Agents, Urinary; D011724:Pyridazines; D002937:Cinoxacin